Capital Viii, Llc Vivo Net Worth

The estimated Net Worth of Capital Viii, Llc Vivo is at least $1.28 Million dollars as of 25 June 2019. Capital Vivo owns over 327,870 units of BioPharmX stock worth over $164,980 and over the last 7 years Capital sold BPMX stock worth over $1,113,706.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Vivo BPMX stock SEC Form 4 insiders trading

Capital has made over 4 trades of the BioPharmX stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital sold 327,870 units of BPMX stock worth $334,427 on 25 June 2019.

The largest trade Capital's ever made was selling 2,000,000 units of BioPharmX stock on 7 March 2018 worth over $720,000. On average, Capital trades about 535,379 units every 129 days since 2017. As of 25 June 2019 Capital still owns at least 317,270 units of BioPharmX stock.

You can see the complete history of Capital Vivo stock trades at the bottom of the page.

What's Capital Vivo's mailing address?

Capital's mailing address filed with the SEC is 192 LYTTON AVENUE, , PALO ALTO, CA, 94301.

Insiders trading at BioPharmX

Over the last 10 years, insiders at BioPharmX have traded over $1,425,057 worth of BioPharmX stock and bought 7,392,667 units worth $2,162,100 . The most active insiders traders include Resources Inc Franklin, Capital Viii, Llc Vivo und Stephen Morlock. On average, BioPharmX executives and independent directors trade stock every 79 days with the average trade being worth of $308,564. The most recent stock trade was executed by Pharmaceuticals Llc Timber on 10 February 2020, trading 55,008 units of BPMX stock currently worth $550.

What does BioPharmX do?

BioPharmX Corp. is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. The HyantX delivery system is designed to stabilize and solubilize hydrophilic molecules in an anhydrous gel environment. The company was founded by James R. Pekarsky and Anja B. Krammer on August 30, 2010 and is headquartered in Campbell, CA.

Complete history of Capital Vivo stock trades at Nabriva Therapeutics Plc und BioPharmX

BioPharmX executives and stock owners

BioPharmX executives and other stock owners filed with the SEC include:

• Lubor Gaal,
  Independent Director
• David Cohen,
  Independent Director
• Edward Sitar,
  Director
• Gianluca Pirozzi,
  Director
• Amir Tavakkol,
  Chief Scientific Officer
• Joyce Goto,
  Chief Accounting Officer
• Zachary Rome,
  Chief Operating Officer, Executive Vice President, Secretary, Director
• Joseph Lucchese,
  Chief Financial Officer, Executive Vice President
• John Koconis,
  Chief Executive Officer, Director
• Michael Derby,
  Executive Chairman of the Board
• Sciences Llc Tardi Med,
  10% owner
• Pharmaceuticals Llc Timber,
  10% owner
• David S Tierney,
  CEO
• Ronald Todd Plott,
  Director
• Stephen Morlock,
  Director
• Kin Foong Chan,
  EVP of R&D
• Anja B Krammer,
  President
• Michael Hubbard,
  Director
• Resources Inc Franklin,
  10% owner
• Capital Viii, Llc Vivo,
  10% owner
• Craig A. Barbarosh,
  Director
• Gregory David Kitchener,
  CFO
• Capital Fund Viii, L.P. Vivo,
  10% owner
• Charles Gregory Vontz,
  Director
• Steven Bosacki,
  Chief Operating Officer